Regulatory milestones

Cubist Pharmaceuticals Inc. (NASDAQ:CBST) was up $0.73 to $73.55 last week after FDA's Anti-Infective Drugs Advisory Committee said it will meet on March 31 to discuss a pair of NDAs covering IV and oral formulations of tedizolid to treat acute bacterial skin and skin structure infections (ABSSSIs). The PDUFA date for both applications is June 20.